United States v. Howen

• Court: District Court, E.D. California
• Decided: April 4, 2022
• Docket: 1:21-cv-00106
• Status: Unknown

Opinion

1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 FOR THE EASTERN DISTRICT OF CALIFORNIA 10 11 UNITED STATES OF AMERICA, No. 1:21-cv-00106-DAD-SAB 12 Plaintiff, 13 v. ORDER GRANTING DEFENDANTS’ MOTION TO STAY 14 LAWRENCE A. HOWEN, et al., (Doc. No. 18) 15 Defendants.

16 17 Before the court is defendants Lawrence A. Howen’s and Nor-Cal Pharmacies, Inc. d/b/a 18 Lockeford Drug’s motion to stay these proceedings, which was filed on December 30, 2021. 19 (Doc. No. 18.) Defendants’ motion was taken under submission to be decided on the papers. 20 (Doc. No. 19.) The government opposed defendants’ motion on February 1, 2022 (Doc. No. 20), 21 and the defendants filed their reply brief on February 8, 2022. (Doc. No. 21.) For the reasons 22 discussed below, the court will grant defendants motion and stay the proceedings in this action. 23 BACKGROUND 24 On January 26, 2021, the government initiated a civil enforcement action against the 25 defendants—a pharmacist and his pharmacy—for violations of the Comprehensive Drug Abuse 26 Prevention and Control Act of 1970 (“Controlled Substances Act” or “CSA”), 21 U.S.C. §§ 801 27 et seq. (Doc. No. 1.) The government seeks civil penalties from defendants for alleged violations 28 of the CSA’s implementing regulations and an order permanently enjoining defendants from 1 dispensing controlled substances. (Id. at ¶¶ 114–127.) Specifically, the complaint’s four counts 2 are for: (1) failure to exercise corresponding responsibility in violation of 21 C.F.R. § 3 1306.04(a); (2) failure to adhere to the usual course of professional practice in violation of 21 4 C.F.R. § 1306.06; (3) failure to maintain required records; and (4) a claim seeking injunctive 5 relief under 21 U.S.C. § 843(f). 6 The statutory and regulatory framework relied on by the government provides as follows: 7 21 U.S.C. § 842(a)(1) makes it unlawful for any person “to distribute or dispense a controlled 8 substance in violation of [21 U.S.C. § 829].” Id. In turn, § 829 generally provides that controlled 9 substances that are deemed prescription drugs may not be dispensed without a written 10 prescription. See 21 U.S.C. § 829. The more specific rules that govern the issuing and filling of 11 prescriptions under § 829 are set forth in regulations 21 C.F.R. §§ 1306.01–1306.27. See 21 12 C.F.R. §§ 1306.01. The government’s first two counts allege violations under two of these 13 implementing regulations. (Doc. No. 1 at ¶¶ 115, 119.) 14 The government’s first count relies on 21 C.F.R. § 1306.04, which provides, in part: 15 A prescription for a controlled substance to be effective must be issued for a legitimate medical purpose by an individual practitioner 16 acting in the usual course of his professional practice. The responsibility for the proper prescribing and dispensing of controlled 17 substances is upon the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription. An 18 order purporting to be a prescription issued not in the usual course of professional treatment or in legitimate and authorized research is not 19 a prescription within the meaning and intent of section 309 of the Act (21 U.S.C. 829) and the person knowingly filling such a purported 20 prescription, as well as the person issuing it, shall be subject to the penalties provided for violations of the provisions of law relating to 21 controlled substances. 22 21 C.F.R. § 1306.04(a). In other words, the regulation provides that an “effective” prescription is 23 one “issued for a legitimate medical purpose” by a prescriber “acting in the usual course of his 24 professional practice.” Id. A prescriber is responsible for properly prescribing and dispensing of 25 “effective” prescriptions, but pharmacists also have a “corresponding responsibility” when filling 26 those prescriptions. Id. More specifically, a pharmacist must not “knowingly” fill prescriptions 27 that purport to be a prescription that was not issued “in the usual course of professional 28 treatment.” Id. In the government’s complaint, the first count alleges that defendants violated 1 this regulation by “knowingly dispensing controlled substances pursuant to prescriptions that 2 were either not issued in the usual course of professional treatment, not issued for a legitimate 3 medical purpose, or both.” (Doc. No. 1 at ¶ 115.) 4 The second count of the government’s complaint relies on 21 C.F.R. § 1306.06, which 5 provides, in part: “A prescription for a controlled substance may only be filled by a pharmacist, 6 acting in the usual course of his professional practice . . ..” Id. As with prescribers in the first 7 sentence of § 1306.04(a), § 1306.06 requires that a pharmacist must act within “the usual course 8 of his professional practice” when filling prescriptions. Id. In the government’s complaint, the 9 second count alleges that defendants “fail[ed] to adhere to the usual course of the professional 10 practice of pharmacy in filling prescriptions for controlled substances.” (Doc. No. 1 at ¶ 119.) 11 On March 12, 2021, defendants filed a motion to dismiss the government’s complaint for 12 failure to state a claim. (Doc. No. 7.) The government opposed the motion (Doc. No. 12) and 13 defendants replied. (Doc. No. 13.) 14 On November 5, 2021, the Supreme Court granted certiorari in a pair of consolidated 15 criminal cases involving both 21 U.S.C. § 841(a)(1) and 21 C.F.R. § 1306.04(a), including the 16 proper construction of the phrase “the usual course of professional practice.”1 See Kahn v. United 17 States, 142 S. Ct. 457 (2021); Ruan v. United States, 142 S. Ct. 457 (2021). Oral argument before 18 the Supreme Court was held in those cases on March 1, 2022. The questions before the Supreme 19 Court in Ruan and Kahn are summarized, in part, as follows: (1) whether a physician accused of 20 prescribing controlled substances acting outside the “usual course of professional practice” may 21 be convicted for violating 21 U.S.C. § 841(a)(1) without regard to whether, in good faith, he or 22 she “reasonably believed” or “subjectively intended” that the prescriptions fall within that course 23 of professional practice; and (2) whether the phrases “usual course of professional practice” and 24 “issued for a legitimate medical purpose” in the first sentence of 21 C.F.R. §§ 1306.04(a) should 25 be read in the conjunctive or disjunctive. See Brief for Petitioner at i, Ruan v. United States, No. 26

27 1 Although this civil action before the court is brought under 21 U.S.C. § 842(a)(1), a criminal action for the unauthorized dispensing of controlled substances may be brought pursuant to 21 28 U.S.C. § 841(a)(1). 1 20-1410 (U.S. filed Dec. 20, 2021), 2021 WL 6138172 at *i; Brief for Petitioner at i, Kahn v. 2 United States, No. 21-5261 (U.S. filed Dec. 20, 2021), 2021 WL 6118301 at *i. 3 On December 30, 2021, defendants filed a motion to stay the proceedings in this case 4 pending the Supreme Court’s rulings in Ruan and Kahn, which defendants contend “could 5 significantly affect” the resolution of the first two counts of the government’s complaint. (Doc. 6 No. 18 at 3.) The government opposed the motion on February 1, 2022, based upon its belief that 7 the Supreme Court will address only “the mens rea the government must establish to secure the 8 [criminal] conviction of a licensed medical practitioner,” in deciding Ruan and Kahn, as well as 9 for other reasons. (Doc. No. 20 at 2.) Defendants filed their reply brief on February 8, 2022. 10 (Doc. No. 21.) 11 LEGAL STANDARD 12 “[T]he power to stay proceedings is incidental to the power inherent in every court to 13 control the disposition of the causes on its docket with economy of time and effort for itself, for 14 counsel, and for litigants.” Landis v. N. Am. Co., 299 U.S. 248, 254 (1936); accord Stone v. INS, 15 514 U.S. 386, 411 (1995) (Breyer, J., dissenting) (“[W]e have long recognized that courts have 16 inherent power to stay proceedings and ‘to control the disposition of the causes on its docket with 17 economy of time and effort for itself, for counsel, and for litigants.’”) (quoting Landis, 299 U.S. 18 at 254). Deciding whether to grant a stay pending the outcome of other proceedings “calls for the 19 exercise of judgment, which must weigh competing interests and maintain an even balance.” 20 Landis, 299 U.S. at 254–55. The party seeking such a stay must “make out a clear case of 21 hardship or inequity in being required to go forward, if there is even a fair possibility that the stay 22 for which he prays will work damage to some one [sic] else.” Id. at 255. 23 In considering whether to grant a stay, this court must weigh several factors, including 24 “[1] the possible damage which may result from the granting of a stay, [2] the hardship or 25 inequity which a party may suffer in being required to go forward, and [3] the orderly course of 26 justice measured in terms of the simplifying or complicating of issues, proof, and questions of law 27 which could be expected to result from a stay.” CMAX, Inc. v. Hall, 300 F.2d 265, 268 (9th Cir. 28 1962) (citing Landis, 299 U.S. at 254–55). A stay may be granted regardless of whether the 1 separate proceedings are “judicial, administrative, or arbitral in character, and does not require 2 that the issues in such proceedings are necessarily controlling of the action before the court.” 3 Leyva v. Certified Grocers of Cal., Ltd., 593 F.2d 857, 864 (9th Cir. 1979). 4 ANALYSIS 5 In their pending motion, defendants argue that the Supreme Court’s decision in Ruan and 6 Kahn will “materially affect this litigation” and that requiring them to defend this suit before 7 those cases are resolved could lead to “irreparable injury.” (Doc. No. 18 at 7–10.) The 8 government counters that defendants must show “a clear case of hardship or inequity” and have 9 failed to do so, that the Supreme Court’s resolution of Ruan and Kahn are unlikely to impact this 10 civil case, and that staying this action would be inefficient. (Doc. No. 20 at 2.) Defendants 11 maintain in their reply brief that the government will not be harmed by the likely short delay 12 because defendants “are not practicing pharmacy and there is no possibility for them to re-start 13 their practice.” (Doc. No. 21 at 4.) Having considered the parties arguments and weighed the 14 relevant factors articulated by the Ninth Circuit, the court will grant defendants motion for a stay 15 of these proceedings pending the Supreme Court’s decision in Ruan and Kahn. 16 First, the court must consider the possible damage that may result from granting the stay. 17 CMAX, 300 F.2d at 268. The government’s complaint seeks civil penalties and a permanent 18 injunction preventing defendants from dispensing controlled substances; a stay would delay the 19 government from potentially obtaining that relief on behalf of the public interest. (Doc. No. 20 at 20 5–6.) At the same time, however, any stay imposed here would be limited in duration to 21 approximately three months because it will end once the Supreme Court issues its decision in 22 Ruan and Kahn, likely in late June or early July 2022 (see https://www.uscourts.gov/about- 23 federal-courts/educational-resources/about-educational-outreach/activity-resources/supreme-1). 24 Cf. Dependable Highway Exp., Inc. v. Navigators Ins. Co., 498 F.3d 1059, 1067 (9th Cir. 2007) 25 (finding a stay that depended on the conclusion of an arbitration being conducted in a foreign 26 country that had not even commenced violated “the general policy favoring stays of short, or at 27 least reasonable, duration”). Here, the government strenuously argues that the fact it is seeking 28 injunctive relief means there is a “fair possibility” of harm to the public interest such that 1 defendants must make out a “clear case of hardship or inequity.” (Doc. No. 20 at 6.) However, 2 the court is not convinced that there is a “fair possibility” of harm here because, unlike in the 3 cases cited by the government, there does not appear to be any ongoing harm in this case. Cf. 4 City of Sacramento v. Wells Fargo & Co., No. 2:18-cv-00416-KJM-GGH, 2019 WL 11093495, 5 at *3 (E.D. Cal. Nov. 20, 2019) (denying a stay when the plaintiffs sought “injunctive relief to 6 prevent ongoing harm from defendants’ [Fair Housing Act] violations”); Lockyer v. Mirant Corp., 7 398 F.3d 1098, 1112 (9th Cir. 2005) (finding a stay to be improper when “the Attorney General 8 seeks injunctive relief against ongoing and future harm”). Here, by contrast, the government 9 alleges in its complaint in this action that defendants ceased operations in 2019 (Doc. No. 1 at ¶¶ 10 107, 113) and their licenses were revoked by the state of California, as acknowledged by the 11 government in its opposition to defendants’ pending motion to dismiss. (Doc. No. 12 at 19) 12 (citing In the Matter of the Accusation Against Nor-Cal Pharmacies; Lawrence Howen, Case No. 13 6781, at *6 (April 30, 2020)).2 Moreover, in opposing the pending motion for a stay the 14 government does not assert any specific ongoing or expected future harm stemming from 15 defendants or their activities. (See Doc. No. 20 at 5–6.) Of course, “[j]ust because injunctive 16 relief is available does not mean the harm persists” or that the court must deny a request for a 17 stay. Mahboob v. Educ. Credit Mgmt. Corp., No. 15-cv-0628-TWR-AGS, 2020 WL 7625144, at 18 *2 (S.D. Cal. Dec. 21, 2020) (granting a stay even when injunctive relief was sought because 19 there was no showing of any ongoing harm). 20 The government also notes its general interests in preserving the quality of evidence and 21 recovering civil penalties. (Doc. No. 20 at 6.) Although these are important interests, the 22 government has not identified any specific evidence it is concerned will deteriorate over the 23 course of the next three months, and in fact, it appears some discovery has already been 24 conducted in this action. (Id.; Doc. No. 18 at 6–7.) The government also has not specifically 25 explained how its interest in collecting civil penalties would be harmed by the granting of the 26 27 2 The California Board of Pharmacy’s decision is available at, 28 https://www.pharmacy.ca.gov/enforcement/fy1920/ac196781.pdf. 1 limited delay were a stay to be granted.3 (Doc. No. 20 at 6–7.) As such, the court does not have a 2 clear basis upon which to find that there would be any harm to these interests in light of the 3 limited duration of the proposed stay. See Burnell v. Swift Transportation Co., No. 5:10-cv- 4 00809-VAP-OP, 2011 WL 13352810, at *5 (C.D. Cal. Jan. 20, 2011) (“While the risk of lost 5 evidence is inherent in every stay, Plaintiffs’ risk in this case is mitigated considerably by the fact 6 that they already have received some informal discovery.”); Grundstrom v. Wilco Life Ins. Co., 7 No. 20-cv-03445-MMC, 2020 WL 6873645, at *2 (N.D. Cal. Oct. 13, 2020) (granting a stay even 8 when injunctive relief and remedial damages were sought and noting that “delay in receiving 9 damages is an insufficient basis to deny a stay”). Accordingly, on balance, the court finds that 10 consideration of this factor is neutral and does not weigh against the granting of the stay sought 11 by defendants. 12 Second, the court must evaluate “the hardship or inequity which a party may suffer in 13 being required to go forward.” CMAX, 300 F.2d at 268. Defendants principally argue that 14 denying their request for a stay “could lead to irreparable injury” due to the “costs of pretrial 15 litigation.” (Doc. No. 18 at 10.) The government maintains that under Ninth Circuit precedent, 16 “being required to defend a suit . . . does not constitute a clear case of hardship or inequity.” 17 (Doc. No. 20 at 7) (quoting Dependable, 498 F.3d at 1066). But the cited quote comes from the 18 Ninth Circuit’s decision in Lockyer where the party opposing the stay had made out a “fair 19 possibility” of harm were a stay to be granted. See Lockyer, 398 F.3d at 1112 (explaining that 20 there was a fair possibility of harm established by the California Attorney General in its suit 21 against an operator of power plants seeking to halt an “ongoing illegal concentration of market 22 power that [was] threaten[ing] economic harm to electricity consumers”). In contrast, “when the 23 3 The cases cited by the government for the proposition that a stay would stultify civil 24 enforcement of federal law are inapposite because in each the court was evaluating a stay that would postpone civil enforcement pending the outcome of a criminal proceeding. (Doc. No. 20 at 25 6–7) (citing United States v. Kordel, 397 U.S. 1, 11 (1970); F.T.C. v. J.K. Publications, Inc., 99 F. Supp. 2d 1176, 1197 (C.D. Cal. 2000); Securities and Exchange Commission v. Zachary J. 26 Horwitz et al., No. 2:21-cv-02927-CAS-GJSX, 2021 WL 2942231, at *4 (C.D. Cal. July 12, 27 2021)). Here, there is no related criminal proceeding against defendants known to the court, and thus the reason—and critically the duration of the proposed stay in this case—is completely 28 different. 1 opponent does not adduce evidence that it will be harmed by a stay[,] . . . courts have considered 2 the moving party’s burden in litigating the case to be a legitimate form of hardship.” 3 Grundstrom, 2020 WL 6873645, at *3. Thus, on balance, the court finds that consideration of 4 this factor to be neutral and does not weigh against the granting of a stay in this case. 5 Third, the court must weigh “the orderly course of justice measured in terms of the 6 simplifying or complicating of issues, proof, and questions of law which could be expected to 7 result from a stay.” CMAX, 300 F.2d at 268. This third factor addresses judicial economy, which 8 “is the primary basis courts consider when ruling on motions to stay.” Vance v. Google LLC, No. 9 5:20-cv-04696-BLF, 2021 WL 534363, at *6 (N.D. Cal. Feb. 12, 2021). Although the court 10 acknowledges that Ruan and Kahn are criminal cases, the Supreme Court’s resolution of the 11 issues posed by those cases could be highly relevant in interpreting the precise regulations before 12 the court in this case. The primary issue in Ruan and Kahn concerns what level of scienter the 13 government must prove to show that a physician acted outside the “usual course of professional 14 practice.” See Brief for Petitioner at i, Ruan v. United States, No. 20-1410 (U.S. filed Dec. 20, 15 2021), 2021 WL 6138172 at *i. In deciding that question, this court believes it is likely that the 16 Supreme Court will also be required to address the meaning of the “usual course of professional 17 practice”—a phrase codified in the regulations at issue in this case and in Ruan and Kahn. 18 Guidance on the appropriate interpretation of this language would “be of valuable assistance to 19 the court” in ruling on the pending motion to dismiss. Leyva, 593 F.2d at 863. For instance, the 20 government’s second count—a violation of 21 C.F.R. § 1306.06—appears to depend entirely on 21 the meaning of the phrase “usual course of professional practice,” and thus the Supreme Court’s 22 ruling in Ruan and Kahn could be critical to this court’s disposition of the pending motion to 23 dismiss that count. The Supreme Court is also addressing the circumstances under which a 24 prescription is deemed valid or “effective” under 21 C.F.R. § 1306.04(a), which in turn, could 25 well affect when pharmacists are to be held liable for knowingly filling prescriptions purporting 26 to be valid or “effective” prescriptions under the same regulation. See Brief for Petitioner at 3, 27 33, Kahn v. United States, No. 21-5261 (U.S. filed Dec. 20, 2021), 2021 WL 6118301 at *3, 33; 28 see also Brief for National Association of Chain Drug Stores as Amicus Curiae Supporting 1 Neither Party at 3, Ruan v. United States, No. 20-1410 (U.S. filed Dec. 27, 2021), 2021 WL 2 6138193 at *3 (arguing that “the Court’s interpretation of 21 C.F.R. § 1306.04—the regulation at 3 the center of Petitioners’ good-faith defense—could have a potentially sweeping effect on 4 pharmacists and the practice of pharmacy”). 5 One other district court faced with a civil enforcement action asserting the same counts as 6 the government asserts in this action has found that the pendency of Ruan and Kahn before the 7 Supreme Court warranted a stay.4 See United States v. Walmart Inc. et al., No. 1:20-cv-01744- 8 CFC, at Doc. No. 59 (D. Del. Nov. 19, 2021). When the district court in Walmart entered its stay, 9 the Supreme Court’s decision in Ruan and Kahn was not expected for seven months, but here the 10 wait would now only be approximately three months. As the district court in Walmart concluded, 11 the short wait to gain the benefit of the Supreme Court’s guidance on the government’s first two 12 counts would promote “the orderly course of justice.” See Leyva, 593 F.2d at 863–84 (“A trial 13 court may, with propriety, find it is efficient for its own docket and the fairest course for the 14 parties to enter a stay of an action before it, pending resolution of independent proceedings which 15 bear upon the case.”). The court therefore finds that consideration of the judicial economy factor 16 weighs heavily in favor of staying this action. 5 17 4 The district court in Walmart issued a summary order on the stay because the government 18 withdrew its opposition to Walmart’s motion seeking that stay. See Walmart Inc. et al., No. 1:20- 19 cv-01744-CFC, Doc. Nos. 58, 59. However, the transcript from the status hearing discussing Ruan and Kahn appears on that court’s docket reflecting the district court’s strong belief that a 20 stay was appropriate given the potential guidance from the Supreme Court’s decision in Ruan and Kahn. See id., Doc. No. 60 at 10–11, 13 (explaining to the litigants that the court has “an 21 unsustainable caseload,” that “from a judicial resource point of view, it makes sense for me to tackle this when I could have a Supreme Court opinion in seven months,” and that the pending 22 motion to dismiss raised “very serious issues about the meaning of these regs and issues . . . that 23 are going to require some serious thought and a lot [] more serious work on my part”).

24 5 The government’s citations to the undersigned’s decisions in Larson v. Harman Mgmt. Corp., No. 1:16-cv-00219-DAD-SKO, 2017 WL 3172979, at *2 (E.D. Cal. July 26, 2017) and Brandt v. 25 Ocwen Loan Servicing, LLC, No. 1:17-cv-00643-DAD-EPG, 2017 WL 5878581, at *4 (E.D. Cal. Nov. 29, 2017) are unpersuasive here. (Doc. No. 20 at 9.) Those cases are inapposite because, 26 among other distinctions, the pending decision that the moving party argued warranted the 27 granting of a stay was from the D.C. Circuit and a Ninth Circuit decision had already been issued dictating the same outcome that would result if the D.C. Circuit ultimately ruled the way that the 28 moving party hoped. Brandt, 2017 WL 5878581, at *4. 1 Accordingly, due to the short length of the proposed stay coupled with the overlap and 2 || expected guidance from the Supreme Court, this court will grant defendants’ motion to stay this 3 | action pending the Supreme Court’s decision in Kahn and Ruan. 4 CONCLUSION 5 For the reasons set forth above, 6 1. Defendants motion to stay (Doc. No. 18) is granted; 7 2. This case is stayed until 14 days after the decision in Kahn v. United States, 142 S. 8 Ct. 457 (2021) and Ruan v. United States, 142 S. Ct. 457 (2021) is issued; and 9 3. The parties are directed to file a joint status report within 14 days after the 10 resolution of Kahn vy. United States, 142 S. Ct. 457 (2021) and Ruan v. United 11 States, 142 S. Ct. 457 (2021) that addresses whether supplemental briefing in light 12 of that decision is necessary in order for the court to resolve defendants’ pending 13 motion to dismiss (Doc. No. 7). 14 | IT IS SO ORDERED. Dated: _ April 1, 2022 J aL Al 5 7 a 16 UNITED STATES DISTRICT JUDGE 17 18 19 20 21 22 23 24 25 26 27 28 10